Latest market price
26.51
+0.22+0.84%
OverviewShort InterestFilings
STOKQT25Stoke Therapeutics, Inc.·NASDAQ
26.51+0.84%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE-4.23%$23.78REPL+2.90%$18.12KLRA-4.98%$12.22NUVB-1.79%$4.67NVAX-3.39%$9.74NTLA-3.57%$12.03MAZE-4.40%$30.10TRAX-1.14%$44.57
Snapshot
Index—P/E—EPS (ttm)-2.83Insider Own21.16%Shs Outstand64.53MPerf Week4.99%
Market Cap1.70BForward P/E—EPS next Y-3.68Insider Trans-0.33%Shs Float45.61MPerf Month1.08%
Enterprise Value1.41BPEG—EPS next Q—Short Float22.49%Perf Quarter-11.06%
Income-7.00MP/S9.22EPS this Y-3116.19%Short Ratio11.70Perf Half Y-20.53%
Sales184.00MP/B4.90EPS next Y—ROA-59.80%Short Interest10.26MPerf YTD-17.17%
Book/sh5.36P/C5.79EPS next 5Y—ROE-67.30%52W High40.22 -34.09%Perf Year-16.30%
Cash/sh4.54P/FCF—EPS past 3/5Y—ROIC-72.01%52W Low20.32 30.46%Perf 3Y651.14%
Dividend Est.—EV/EBITDA—Sales past 3/5Y148.43% —Gross Margin88.52%Volatility3.90% 4.98%Perf 5Y8.23%
Dividend TTM—EV/Sales7.64EPS Y/Y TTM-665.67%Oper. Margin-913.12%ATR (14)1.22Perf 10Y—
Dividend Ex-Date—Quick Ratio7.24Sales Y/Y TTM-86.96%Profit Margin-862.07%RSI (14)52.31Recom2.19
Dividend Gr. 3/5Y—Current Ratio7.24EPS Q/Q-66.15%SMA205.19%Beta1.32Target Price50.50
Payout0.00%Debt/Eq0.01Sales Q/Q0.00%SMA50-4.15%Rel Volume1.83Prev Close26.29
Employees170LT Debt/Eq0.00EarningsMar 15SMA200-14.97%Avg Volume1.01MPrice26.51
IPO DateJun 19, 2019Option/ShortYes / YesEPS/Sales Surpr.-16.24% 37.06%Net Debt/EBITDA—Volume1,856,808Change0.84%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-30-26ReiteratedGoldman Sachs$44 → $43
Aug-04-26ReiteratedCanaccord GenuityBuy$36 → $58
Jul-13-26InitiatedGoldman SachsBuy$44
Feb-23-26InitiatedWolfe ResearchOutperform$40
Feb-05-26InitiatedGuggenheimBuy$60
Jan-12-26ReiteratedWedbushOutperform$36
Jan-05-26ReiteratedLoop Capital Markets$35
Jan-05-26ReiteratedCanaccord GenuityBuy$28 → $36
Dec-15-25ReiteratedUBSNeutral$35 → $50
Dec-15-25ReiteratedHC Wainwright & Co.Buy$35 → $50
Latest News· Times ET
Oct-30-26
Oct-30-2601:58AM
Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcriptseekingalpha.com
Oct-29-26
Oct-29-2610:15PM
Stoke Therapeutics Q3 Earnings Call Highlightsmarketbeat.com
08:06PM
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimateszacks.com
Oct-27-26
Oct-27-2610:31AM
Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsightYahoo
Oct-22-26
Oct-22-2609:00AM
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updatesgurufocus.com
Oct-19-26
Oct-19-2604:34PM
Stoke Therapeutics: The Market Misread A Key FDA Winseekingalpha.com
Oct-16-26
Oct-16-2604:20PM
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)businesswire.com
Oct-12-26
Oct-12-2608:00AM
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meetingbusinesswire.com
04:07AM
Stoke Therapeutics Presents Data For STK-002 Supporting Disease-Modifying Potential In Autosomal Dominant Optic Atrophy At AAO 2026 Annual MeetingBenzinga
Oct-06-26
Oct-06-2608:00AM
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meetingbusinesswire.com
Oct-05-26
Oct-05-2608:00AM
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndromegurufocus.com
03:10AM
Government Study: Cellphone Radiation Linked To CancerBenzinga
Sep-28-26
Sep-28-2603:25AM
Stoke Therapeutics, Inc. $STOK Shares Newly Acquired by Corient Private Wealth LPdefenseworld.net
Sep-23-26
Sep-23-2604:01PM
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercializationbusinesswire.com
Sep-18-26
Sep-18-2604:34AM
Squarepoint Ops LLC Acquires Shares of 29,310 Stoke Therapeutics, Inc. $STOKdefenseworld.net
Company

Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue184379——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit184379——————
Selling, General and Administrative Excl. Other674941——————
Research and Development1388982——————
Other Operating Expense001——————
Operating Income-21-101-115——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)141210——————
Net Income Before Taxes-7-89-105——————
Income Taxes
000——————
Consolidated Net Income-7-89-105——————
Net Income From Continuing Operations-7-89-105——————
Net Income-7-89-105——————
EPS (Recurring)-0.12-1.65-2.38——————
EPS (Basic, Before Extraordinaries)-0.12-1.65-2.38——————
EPS (Diluted)-0.12-1.65-2.38——————
EBITDA-5-87-102——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio10.1816.1025.72——————
Gross Margin100.00100.00100.00——————
Operating Margin-11.41-272.97-1,277.78——————
Net Margin-3.80-240.54-1,166.67——————
Shares Outstanding595444——————
Market Capitalization1,873596231——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$41.27$34.94$28.61$22.28$15.95● Close Price0.00M0.78M1.56M2.34M3.13MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Allan JonathanGENERAL COUNSEL & CORP SECOct 02 '26Sale26.3362716,50920,598Oct 02
Ticho BarryCHIEF MEDICAL OFFICEROct 01 '26Sale26.161,05127,49419,059Oct 02
Ticho BarryCHIEF MEDICAL OFFICERSep 01 '26Sale30.675,545170,06120,110Sep 03
Kaye Edward M. MDDirectorAug 18 '26Sale32.0312,567402,528124,557Aug 18
Ticho BarryCHIEF MEDICAL OFFICERAug 18 '26Sale32.034,767152,69025,655Aug 18
Allan JonathanGENERAL COUNSEL & CORP SECAug 18 '26Sale32.032,86191,64021,225Aug 18
Ticho BarryCHIEF MEDICAL OFFICERAug 14 '26Option Exercise0.0010,000030,422Aug 18
Kaye Edward M. MDDirectorAug 14 '26Option Exercise0.0026,2500137,124Aug 18
Allan JonathanGENERAL COUNSEL & CORP SECAug 14 '26Option Exercise0.006,000024,086Aug 18
Ticho BarryCHIEF MEDICAL OFFICERAug 03 '26Sale29.047,176208,38520,422Aug 05
Ticho BarryCHIEF MEDICAL OFFICERJul 01 '26Sale32.667,228236,06827,598Jul 06
Allan JonathanGENERAL COUNSEL & CORP SECJun 16 '26Sale29.951,45743,63718,086Jun 18
Ticho BarryCHIEF MEDICAL OFFICERJun 01 '26Sale30.581,79554,89134,826Jun 03
Ticho BarryCHIEF MEDICAL OFFICERMay 01 '26Sale32.792,24373,54836,621May 05
Ticho BarryCHIEF MEDICAL OFFICERApr 01 '26Sale32.661,83860,02938,864Apr 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.